Home›Allergy & Immunology› Triple consolidation with CAR T cells yields sustained remission in relapsed BPDCN
Triple consolidation with CAR T cells yields sustained remission in relapsed BPDCNNew treatment strategy shows promise for rare blood cancer
Frontiers in MedicinePublished July 31, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider CD123 CAR T-cell consolidation as a potential option for relapsed BPDCN without a donor, but weigh toxicity risks.
This publication is a case report and review of the literature, focusing on a 55-year-old male with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) with central nervous system involvement, who lacked a suitable HLA-matched donor. The authors describe a triple-integrated consolidation strategy comprising Hyper-CVAD chemotherapy, high-dose conditioning with autologous stem cell transplantation (ASCT), autologous CD123 CAR T-cell infusion (1.74x10^6/kg), and venetoclax maintenance.
The patient achieved a sustained MRD-negative complete metabolic response, with disease-free survival exceeding 13 months. The authors report 1 out of 1 patient achieving this outcome. However, the treatment was associated with significant toxicity, including grade 3 cytokine release syndrome, suspected immune effector cell-associated HLH-like syndrome (IEC-HS), and CAR-T-induced prolonged cytopenia.
The authors note that this is a single case report, and results are not generalizable to the broader BPDCN population. The lack of a comparator and the absence of reported p-values or confidence intervals further limit the strength of the evidence.
Despite these limitations, the report suggests a feasible and potentially curative alternative for BPDCN patients in the 'no-donor' setting. Clinicians should interpret these findings cautiously, recognizing that this approach requires further validation in larger studies before it can be considered standard of care.
How this fits prior evidence
This case report extends prior coverage on venetoclax-based regimens in hematologic malignancies, specifically the meta-analysis showing 63.79% ORR in relapsed/refractory AML. Here, venetoclax is used as maintenance after CAR T-cell therapy in BPDCN, suggesting a broader role for venetoclax in consolidation. It also contrasts with prior findings on CAR T-cell toxicity, as this case reports grade 3 CRS and suspected IEC-HS, reinforcing the need for careful monitoring. The report addresses a gap in treatment options for BPDCN patients without a donor, but as a single case, it provides only preliminary evidence.
Imagine facing a rare and aggressive blood cancer where the standard path to recovery is blocked because you cannot find a matching bone marrow donor. This was the reality for a 55-year-old man with a condition called blastic plasmacytoid dendritic cell neoplasm. He needed a way to fight the disease when traditional options were unavailable.
Doctors used a three-part strategy to treat him. This included intense chemotherapy, a stem cell transplant using his own cells, and a specialized CAR T-cell infusion followed by maintenance medicine. The goal was to create a durable response in a patient who otherwise had very few choices.
This specific approach worked for him. He achieved a complete metabolic response and remained free of detectable disease for over 13 months. While the treatment caused serious side effects like cytokine release syndrome, it provided a potential new path for others facing this same rare diagnosis without a donor.
What this means for you:
A multi-step strategy using CAR T-cells and other therapies may offer hope for patients with rare blood cancers.
Common questions
What is this treatment and how does it work?
The treatment used a three-part approach. It combined intensive chemotherapy, a stem cell transplant using the patient's own cells, and a CAR T-cell infusion. This was followed by maintenance medicine to keep the cancer away.
Is this treatment safe for patients?
The treatment caused serious side effects in this case, including Grade 3 cytokine release syndrome and a condition called IEC-HS. It also caused prolonged low blood cell counts. Talk to your doctor about specific risks.
Who can benefit from this new approach?
This treatment is specifically noted as a potential option for patients with blastic plasmacytoid dendritic cell neoplasm who do not have a suitable bone marrow donor available for transplant.
More on Blastic plasmacytoid dendritic cell neoplasm
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy with limited therapeutic options for patients ineligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT). While CD123-targeted therapies and CAR T-cell infusion have shown promise, achieving durable remission without consolidative transplantation remains challenging. We report a pioneering “triple-integrated” consolidation strategy in a 55-year-old male with relapsed/refractory BPDCN and central nervous system involvement who lacked a suitable HLA-matched donor. After achieving a complete metabolic response with persistent bone marrow minimal residual disease (MRD) following Hyper-CVAD chemotherapy, the patient underwent high-dose conditioning and autologous stem cell transplantation (ASCT) sequentially followed by autologous CD123 CAR T-cell infusion (1.74×106/kg). The clinical course was complicated by Grade 3 cytokine release syndrome and suspected immune effector cell-associated HLH-like syndrome (IEC-HS), which were successfully managed with glucocorticoid and emapalumab. Notably, ASCT served as a “hematopoietic rescue” for CAR-T-induced prolonged cytopenia. To prevent late clonal escape, maintenance therapy with the BCL-2 inhibitor venetoclax was initiated post-transplant. The patient achieved sustained MRD-negative CR with a disease-free survival exceeding 13 months. This multimodal paradigm—combining intensive cytoreduction, targeted immunotherapy with marrow rescue, and molecular maintenance—provides a feasible and potentially curative alternative for BPDCN patients in the “no-donor” setting.
